8-K: Senseonics Reports Record Q2 Revenue, Raises Full-Year Guidance

Senseonics Holdings, Inc. announced record second quarter 2026 revenue of $14.5 million, a 120% year-over-year increase, and raised its full-year revenue and gross margin guidance.

Summary

• Senseonics Holdings, Inc. reported record second quarter 2026 revenue of $14.5 million, a 120% increase compared to $6.6 million in Q2 2025.
• U.S. revenue grew over 150% year-over-year to $12.6 million, marking the highest quarterly shipment volume in company history.
• Gross margin for Q2 2026 was approximately 59%, up from 47% in Q2 2025.
• The company raised its full-year 2026 revenue guidance to $62 million-$66 million (76%-87% growth) and gross margin guidance to 58%-61%.
• Net loss for Q2 2026 was $36.7 million ($0.63 per share), compared to a net loss of $14.5 million ($0.36 per share) in Q2 2025.
• Cash and cash equivalents totaled $143.0 million as of June 30, 2026, following a capital raise of over $100 million in Q2.
• Commercial operations in the U.S. and Europe are now fully in-house, with the European transition completed in June 2026.
• Development programs for Gemini and Freedom are advancing.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive report, driven by significant year-over-year revenue growth, raised guidance, and successful integration of European operations, indicating robust operational execution and market traction.

Positives

• Generated record second quarter revenue of $14.5 million, a 120% increase year-over-year.
• Raised full-year 2026 revenue guidance to $62 million-$66 million, representing 76%-87% year-over-year growth.
• Achieved Q2 gross margin of approximately 59%, exceeding previous guidance and up from 47% in Q2 2025.
• Raised full-year gross margin guidance to 58%-61%.
• Strong U.S. commercial momentum with revenue up over 150% year-over-year and active prescribers up 130%.
• Successfully completed the commercial transition of European business in-house.
• Strengthened balance sheet by raising over $100 million in Q2 2026.
• Eon Care adoption is scaling, reaching 40% of insertion procedures.

Negatives

• Net loss for Q2 2026 was $36.7 million, a significant increase from $14.5 million in Q2 2025.
• Research and development expenses increased to $11.6 million in Q2 2026 from $7.7 million in Q2 2025, due to Gemini and Freedom development.
• Selling, general and administrative expenses increased substantially to $32.9 million in Q2 2026 from $9.7 million in Q2 2025, primarily due to commercial integration and European transition costs.
• Basic net loss per common share was $0.63 in Q2 2026, compared to $0.36 in Q2 2025.

Risks

• Risks and uncertainties related to the continued commercial transition and roll-out of Eversense 365 in the European Union, including the timing of tender updates.
• Risks related to the pace of Eon hiring and network scaling.
• Uncertainties in insurer, regulatory, and administrative processes and decisions.
• Uncertainties in finalizing integration and commercial terms and coordination with health systems and other collaboration partners and third parties.
• Uncertainties inherent in the ongoing commercialization and expansion of the Eversense product and Senseonics and its partners activities.
• Uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs.
• The company's ability to satisfy conditions for future borrowings under the Hercules facility.

Future Outlook

Senseonics is raising its full-year 2026 global net revenue guidance to $62 million to $66 million (76%-87% growth) and its full-year gross margin guidance to 58% to 61%. The outlook reflects ongoing roll-out of Eversense 365, direct-to-consumer marketing, sales initiatives, and patient assistance programs.

Management Comments

• "This was the strongest quarter in Senseonics history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs," said Tim Goodnow, PhD, President and Chief Executive Officer.
• "Revenue grew approximately 120% year-over-year, and we delivered gross margin above our guided range for the second consecutive quarter, which validates the decision we made to bring our commercial organization fully in-house."
• "The European commercial CGM organization is now integrated into Senseonics, and Eon Care continues to scale as one of our most important growth drivers. Given our momentum, we're raising our full-year revenue and margin guidance. We're not just growing the business we're redefining what a CGM can be."
• "Our commercial momentum continues to build, with strong U.S. direct-to-consumer results, now representing our largest source of new patients, improved productivity across our health care provider channel, and continued expansion of Eon Care," added Brian Hansen, Chief Commercial Officer.
• "We were also encouraged by continued uptake of Eversense 365 in combination with the twiist Automated Insulin Delivery system. We look forward to continuing to drive performance with Eversense global commercialization now fully under Senseonics control."

Industry Context

StockSavvy.ai notes that Senseonics' strong performance and raised guidance align with a growing market for continuous glucose monitoring systems, driven by increasing diabetes prevalence and technological advancements in diabetes management. The company's strategic move to bring commercial operations in-house appears to be yielding positive results, differentiating it in a competitive landscape.

Comparison to Industry Standards

• Senseonics' Q2 2026 revenue growth of 120% significantly outpaces the typical growth rates seen in many established medical device companies, though it is within the range of high-growth emerging companies.
• The Q2 gross margin of 59% is strong for a medical device company, particularly one with complex implantable technology, and is moving towards the higher end of the company's own raised guidance range.
• Competitors like Dexcom and Abbott also report strong growth in the CGM market, but Senseonics' year-over-year percentage growth is particularly notable given its recent operational changes.
• The company's focus on long-term implantable sensors (up to 365 days) is a key differentiator compared to many disposable sensor competitors, potentially impacting cost-effectiveness and patient adherence over time.

Related Party Transactions

• Revenue, net related parties was $1,808 thousand for Q2 2026, compared to $3,426 thousand for Q2 2025.
• Accounts receivable, net related parties was $1,132 thousand as of June 30, 2026, compared to $5,312 thousand as of December 31, 2025.
• Accrued expenses and other current liabilities, related parties was $3,823 thousand as of June 30, 2026, compared to $5,198 thousand as of December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from raised guidance, record revenue, and successful capital raise, potentially leading to increased valuation.
• Employees: Potential for increased job security and growth opportunities due to company expansion and successful integration of operations.
• Customers (Patients): Continued access to and potential improvement of CGM technology, with Eon Care scaling to improve insertion procedures.
• Healthcare Providers: Increased adoption of Eversense and Eon Care, potentially simplifying diabetes management workflows.
• Creditors: Improved financial position due to capital raise and strong revenue growth, reducing financial risk.

Next Steps

• Continue scaling Eon Care, with a year-end goal of 100 nurses.
• Advance Gemini and Freedom development programs.
• Continue global commercialization of Eversense.
• Monitor and manage European commercial transition dynamics.

Key Dates

Recommendation

The filing demonstrates exceptionally strong operational execution with record revenue growth, significant margin expansion, and successful integration of key commercial operations. The raised full-year guidance, coupled with a strengthened balance sheet from a substantial capital raise, indicates a positive trajectory and undervaluation relative to growth prospects. The company is executing well on its strategic initiatives, making it an attractive investment.

Keywords

continuous glucose monitoring, CGM, diabetes, Eversense, medical technology, financial results, revenue guidance, gross margin